Abstract
Cardiometabolic disease, spanning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk, represents a major public health burden. Advances in preclinical translational science point to potential targets across multiple organ systems for early intervention to improve cardiometabolic health. Validation in clinical trials and translation to care would benefit from in vivo diagnostic techniques that facilitate therapeutic advancements. This review provides a state-of-the-art, multimodality perspective spanning the multiple organ systems that contribute to cardiometabolic disease.
Keywords:
cardiovascular diseases; diabetes mellitus, type 2; humans; obesity; risk factors.
© 2017 American Heart Association, Inc.
MeSH terms
-
Adipose Tissue / diagnostic imaging*
-
Adipose Tissue / metabolism
-
Adipose Tissue / physiopathology
-
Animals
-
Cardiovascular Diseases / diagnostic imaging*
-
Cardiovascular Diseases / epidemiology
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / physiopathology
-
Energy Metabolism
-
Heart / diagnostic imaging*
-
Humans
-
Liver / diagnostic imaging*
-
Liver / metabolism
-
Liver / physiopathology
-
Metabolic Syndrome / diagnostic imaging*
-
Metabolic Syndrome / epidemiology
-
Metabolic Syndrome / metabolism
-
Metabolic Syndrome / physiopathology
-
Multimodal Imaging / methods*
-
Muscle, Skeletal / diagnostic imaging*
-
Muscle, Skeletal / metabolism
-
Muscle, Skeletal / physiopathology
-
Myocardium / metabolism
-
Pancreas / diagnostic imaging*
-
Pancreas / metabolism
-
Pancreas / physiopathology
-
Predictive Value of Tests
-
Prognosis
-
Risk Factors